EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer

Fausto Petrelli, Antonio Ghidini

JAMA · 2024

DOI: 10.1001/jama.2024.15491 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2024. Verfasst von Fausto Petrelli und 1 weiteren Autor:innen. Beteiligte Einrichtung: ASST Bergamo Ovest, Treviglio (BG), Italy. Hauptthemen laut MEDLINE: Aspirin, Breast Neoplasms. Die Arbeit nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor A recent study1 that investigated the effects of aspirin on breast cancer recurrence in high-risk patients with nonmetastatic disease concluded that daily aspirin therapy did not reduce breast cancer recurrence or improve survival. We have some comments about this study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinBreast NeoplasmsFemaleHumansAnti-Inflammatory Agents, Non-SteroidalChemotherapy, AdjuvantRandomized Controlled Trials as TopicNeoplasm Recurrence, LocalPlacebosMulticenter Studies as TopicClinical Trials, Phase III as TopicNeoplasm InvasivenessDisease-Free Survival

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAspirinPlacebos

Autor:innen und Institutionen

  • ASST Bergamo Ovest, Treviglio (BG), Italy.
  • Casa di cura Igea, Milan, Italy.

Zitieren

APA

Petrelli, F., & Ghidini, A. (2024). Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. https://doi.org/10.1001/jama.2024.15491

Vancouver

Petrelli F, Ghidini A. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer. JAMA. 2024. doi:10.1001/jama.2024.15491

BibTeX
@article{Petrelli2024,
  author = {Petrelli, Fausto and Ghidini, Antonio},
  title = {Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.15491}
}
Kostenlos starten →